You are here
Treatment evolution in advanced GI malignancies
Official Sponsored Satellite Symposium at ECCO 2017: European Cancer Congress. 29 January 18:45 – 20:15
During this symposium, a distinguished faculty of experts engaged the audience in an interactive discussion on how to optimize the day-to-day management of patients with gastrointestinal malignancies. Using patient cases from their clinical practices, the experts exemplify how treatment has evolved over the years into the current best-treatment strategies. The final presentation covers the latest clinical evidence of how these strategies may continue to evolve in the future.
Learning objectives based on identified educational needs
- Describe the evolution of metastatic colorectal cancer (mCRC) management and progress in treatment of advanced/metastatic gastric and gastro-oesophageal junction (GEJ) cancer to its current status in recent years
- State the evidence supporting the design of current optimal treatment strategy for patients with advanced/metastatic GEJ cancer and mCRC
- Develop a care plan that aims to achieve optimal treatment benefits and maximize individual patient outcomes in patients with advanced/metastatic GEJ cancer and mCRC in daily clinical practice
- Formulate the remaining unmet needs in the treatment of patients with locally advanced or metastatic gastric/GEJ cancer and mCRC and understand how ongoing research could further improve outcomes in patients with advanced/metastatic GEJ cancer and mCRC
Florian LordickThis symposium focuses on gastric cancer and colorectal cancer in the advanced stages and looks at clinical trial data, multi-disciplinary...
Naureen StarlingNew ESMO clinical practice guidelines on gastric cancer were published in 2016. Dr Starling takes the audience on a journey that addresses: the advances in chemotherapy treatments over the past 2 decades, the impact of targeted therapies, and the relatively new area of checkpoint inhibitors. She summarises many of the negative clinical trial results and highlights emerging areas of clinical research in advanced/metastatic gastric and gastroesophageal junction (GEJ) cancer.
Eric Van CutsemNew ESMO clinical practice guidelines on metastatic colorectal cancer were published in 2016. Dr Van Cutsem builds real-life scenarios around these guidelines using case studies and interactive questions where he asks the audience to select a treatment option for each case study. Based on the answers, he then engages the panel to contribute their expertise to explain why they would select a particular option over another in their practices.
Nicole van GriekenDr van Grieken, a pathologist, presents the past, present and future status of molecular biology in tumour research. She reviews the history of technological development that has led to molecular markers, comments on how comprehensive molecular analyses is improving our understanding of tumour biology and clinical behaviour, and addresses the challenges that remain in making molecular markers useful predictive tools. She also reviews the exciting potential value of liquid biopsies for diagnosis and follow up in cancer patients.